Background. To assess clinical outcomes of patients with concomitant severe aortic stenosis (AS) and coronary artery disease (CAD) who underwent transcatheter aortic valve implantation (TAVI) and percutaneous coronary intervention (PCI) or surgical aortic valve replacement (SAVR) and coronary artery bypass grafting (CABG).
INTRODUCTION
Coronary artery disease (CAD) is common in patients with severe aortic stenosis (AS), which does not surprise because these two pathologies share many causative factors [1] . The presence of concomitant CAD has been associated with adverse procedural outcomes in aortic valve replacement [2, 3] .
If in surgical patients the current standard of care for patients with concomitant AS and CAD is to combine coronary artery bypass grafting (CABG) with surgical aortic valve replacement (SAVR) in the same session [4, 5] , optimal management of CAD in the context of transcatheter aortic valve implantation (TAVI) is highly debated due to the lack of comprehensive and consistent data on this topic [6, 7] . However, in clinical practice, prophylactic percutaneous coronary intervention (PCI) or concomitant TAVI and PCI of coronaries supplying large myocardial areas are the most adopted approaches [7] [8] [9] [10] .
The comparative efficacy of TAVI and SAVR has been extensively investigated in large randomized trials [11] [12] [13] [14] and propensity matched-based observational studies [15] . However, patients with CAD requiring coronary revascularization were excluded from the majority of randomized trials or poorly investigated, thus creating an important gap in the current evidence [11] [12] [13] [14] .
To shed light on this controversial area, we report on the mid-term clinical outcomes of a large series of patients with concomitant severe AS and CAD who underwent TAVI and PCI or SAVR and CABG and were recruited in the Italian national multicenter OBSERVANT (Observational Study of Effectiveness of SAVR-TAVI Procedures for Severe Aortic Stenosis Treatment) study.
METHODS

Study design and data quality assessment -OBSERVANT is a national observational,
prospective, multicenter, cohort study that enrolled consecutive patients undergoing TAVI or SAVR for severe aortic valve stenosis at 93 Italian cardiology/cardiac surgery centers. Details on the study design, patient eligibility criteria, and data collection modalities of the OBSERVANT registry have been reported elsewhere [16, 17] . This study was coordinated by the Italian National Institute of Health and led in cooperation with the Italian Ministry of Health, the National Agency for Regional Health Services, Italian Regions, and Italian scientific societies and federations representing Italian professionals involved in the management of severe AS. In the participating hospitals, both SAVR and TAVI were available options. Techniques and choice of the prosthesis were left to the operator's discretion according to local pre-interventional workout and institutional practice. The Ethical Committee of each participating center approved the study protocol, and patients gave their informed consent to participate in the study.
Patient population -Invasive coronary angiography was mandatory in all patients and was
assessed by the local heart team. In case of significant CAD (i.e., >50% diameter stenosis on visual assessment of the coronary angiogram), the treatment strategy and completeness of revascularization was determined based on consensus decision before TAVI or SAVR at each participating center. For the purposes of the present analysis, we included only patients with established CAD (i.e., documented by coronary angiography) meeting any of the following inclusion criteria: 1) TAVI patients with CAD undergoing PCI prior to the procedure (i.e., <6 months before TAVI) or combined TAVI and PCI in the same session; 2) SAVR patients undergoing combined SAVR and CABG in the same session. Inoperable patients (i.e. porcelain aorta and hostile thorax) and patients undergoing hybrid PCI and CABG procedures, concomitant interventions in other valves, or those undergoing TAVI non-transfemoral access were excluded.
Outcomes of interest -
The primary outcomes of interest were all-cause mortality and the composite of death, myocardial infarction, stroke and unplanned revascularization at 30 days, 1, 2 and 3 years from SAVR or TAVI. Unplanned revascularization was defined as any revascularization procedure (CABG or PCI) performed at least 30 days after the index intervention or as revascularization for acute myocardial infarction at any time point.
Follow up -As part of the OBSERVANT study, an administrative follow-up has been set up for each enrolled patient through a record linkage with the National Hospital Discharged Records (HDR) database (for in-hospital events: re-hospitalization, stroke, acute myocardial infarction, PCI and CABG) and with the Tax Registry Information System (TRIS) (for information on life status).
Specific quality assessment activities were arranged to evaluate the reliability and coherence of the OBSERVANT database. In particular, independent observers, following specific standard operating procedures, monitored the participating hospitals to assess the completeness of the enrolled cohort and to compare the collected data to those reported in the original clinical charts.
Statistical analysis -Continuous variables are reported as mean and standard deviation (SD)
while dichotomous parameters as frequencies and percentages (%). The normal distribution of continuous parameters was tested with the Kolgomorov-Smirnov test. Variables with a skewed distribution were compared with the use of Wilcoxon rank sum tests. T-test, Chi-square or Fisher exact tests were used to compare frequencies among groups, as appropriate. Unadjusted event rates at follow-up were plotted according to the Kaplan-Meier method and differences in survival were tested with the log-rank test. We used the cumulative incidence function to account for the the competing risk of death with other events of interest (e.g. MI, stroke and unplanned revascularization). We then compared the cumulative incidence functions between SAVR and TAVI groups using the Gray test.
Propensity score matching -To account for the non-randomized design of our study, the a propensity score has been developed estimated using a logistic regression model according to a non-parsimonious approach. The following clinical pre-procedural variables were included in the model: age, gender, chronic obstructive pulmonary disease, diabetes, history of myocardial infarction, left ventricular ejection fraction, neurological disease, creatinine and hemoglobin levels, dialysis, Euroscore II-estimated risk of 30-day mortality, frailty, New York Heart Association functional class III or IV at presentation, moderate-to-severe mitral regurgitation, peripheral artery disease, mean gradient, pulmonary hypertension. Pairs of SAVR and TAVI patients having the same probability score (nearest neighbor method; caliper=0.25*SD (logitPs)) have been matched with a 1:1 ratio. Standardized mean differences before and after matching have beenwere calculated and a standardized difference below 0.110% has beenwas considered as a criterion of balance between the study cohorts. n index of proper balance. In addition to weighting, a simultaneous multivariate adjustment (doubly robust estimate) was performed for covariates included in the propensity score model with an absolute standardized difference > 10% after weighting. Finally, predicted probabilities of survival from the adjusted Cox-model were obtained and plotted for the principal outcomes of interest.
All tests performed in the current analysis arewere two-tailed and a p-value <0.05 has beenwas considered statistically significant. All statistical analyses were conducted inperformed using R statistical software (version 3.2.1) equipped with the "twang" and "survival" packages. Clinical characteristics between the SAVR and TAVI groups are shown in Table 1 . As expected, before matching there was a marked unbalance in covariates between the two groups.
RESULTS
Propensity scores balance -After matching, a total of 236 pairs of patients were identified.
Differences between TAVI and SAVR patients were well corrected for most of covariates, with all standardized differences below 0.2.except for creatinine, dialysis and low LVEF (< 30%), with standardized differences slightly above 10% (12.6, 10.8 and 11.6%, respectively). To take into Three-year clinical outcomes -Administrative linkage was carried out in 100% of patients.
Survival curves for SAVR and TAVI matched cohorts are shown in Figure 1 . At 3-year, there was no difference in survival between the two groups (KM estimate of freedom from death for SAVR and TAVI patients of 0.742 and 0.650, respectively; log-rank p-value of 0.105). Similarly, the rate of MACCE was comparable between the two groups (KM estimate of freedom from MACCE for SAVR and TAVI patients of 0.683 and 0.582, respectively; log-rank p-value of 0.115). The cumulative number of events for MACCE and death at different follow-up intervals is reported in Table 2 . The cumulative incidence of MI, stroke and revascularization is shown in Table 3 . There were no differences between the two groups for all these endpoints at 3-year follow-up (all p-values by Gray test >0.05).
DISCUSSION
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The principal finding of this study including a population of patients with associated severe AS and CAD was that a fully percutaneous treatment (TAVI and PCI prior to or combined during the procedure) was comparable to surgical treatment (SAVR and concomitant CABG) with respect to the 30-day, 1 year and 3-year rates of death from any cause, stroke, myocardial infarction and unplanned revascularization. However, at 3 years, a trend toward lower survival from death and from the composite of death, MI, stroke and unplanned revascularization in patients treated with TAVI.
Despite the availability of several head-to-head comparisons between TAVI and SAVR in randomized clinical trials and meta-analyses of elderly patients at high and intermediate surgical risk [11] [12] [13] [14] [15] , it is still unknown which approach performs better when severe AS and CAD coexist in this particular population. In fact, concomitant CAD requiring treatment was an exclusion criterion of the majority of the most representative trials comparing SAVR and TAVI (PARTNER 1, CoreValve U.S. and NOTION) [11] [12] [13] , and was not deeply investigated in the PARTNER 2 trial. However, CAD patients represent a sizeable proportion of subjects referred to TAVI or SAVR in real-world practice. CAD is frequently seen in patients with severe AS [1, 7] . Therefore, understanding which approach should be preferred in patients with both pathologies would have a great impact, particularly in the current era, in which TAVI is being increasingly used to treat younger and lower risk patients with a longer life expectancy than those who underwent TAVI in the past. This analysis of the OBSERVANT study aims to fill this important evidence gap, until properly designed randomized trials will be available.
According to the most recent North American and European guidelines, SAVR patients with significant CAD should undergo concomitant CABG [4, 5] , as it was demonstrated that this approach reduces both short-term mortality and increases long-term survival up to 10 years [19] . On the contrary, optimal management of CAD in the context of TAVI is highly debated [7] . There is only a general consensus that severe coronary lesions that subtend a large area of myocardium such as proximal epicardial lesions should be considered for PCI before or eventually at the time of TAVI [7] . According to these different treatment strategies, it is reasonably assumed that complete revascularization is considerably more often obtained in surgical patients as compared with those undergoing TAVI and PCI [7, 9, 10] . Whether these two strategies lead different outcomes in elderly and intermediate or high-risk patients remains to be determined. Indeed, this study represents the first attempt to shed more light on this topic.
In our study, we demonstrated that the death from any cause and MACCE rates up to 3 years were similar in the percutaneous and surgical groups, even though it must be pointed out that at 3 years, there was a trend toward increased mortality and cumulative MACCE rates in TAVI patients.
We did not observe significant differences in terms of myocardial infarction and stroke. A potential contributing explanation for this finding might be a lower rate of complete revascularization obtained in TAVI patients with PCI as compared with CABG. Indeed, CAD left untreated may be the substrate for future cardiovascular events leading to a marginal increase in the risk of mortality at long-term follow-up. It has to be acknowledged that the actual need for complete revascularization in TAVI patients is poorly investigated and that the extent of residual CAD left untreated may differ based on age and individual risk characteristics [20, 21] . Indeed, Girerd et al. found that incomplete revascularization did not have an impact on survival in patients >60 years of age, suggesting that in this particular elderly patient population at high operative risk, pursuing complete revascularization is not mandatory, provided that a rational approach to CAD by a dedicated heart team is guaranteed [20] . More recent studies on TAVI patients also confirmed this observation, showing that as long as the target population is old and at high-risk, a judicious revascularization strategy selection is associated with favorable mid-term outcomes, obviating the need for complete CAD revascularization [9] [10] . The concept of reasonable extent of residual CAD left untreated after PCI or CABG has been the object of numerous investigations [22, 23] , but whether this also applies to the TAVI scenario is unknown and deserves future investigations. The actual need for PCI compared with medical therapy in TAVI patients is the object of an ongoing trial (ISRCTN75836930) [24] .
Finally, it should be acknowledged that among the OBSERVANT study, TAVI patients were treated with previous-generation devices; technical developments with newly generation of percutaneous valves are already showing to reduce a procedural gap in comparison to SAVR in patients with isolated AS [25] .
Study limitations -This study has different limitations. First, it is not a randomized trial.
Although we conducted an extensive statistical adjustment (including a 1:1 propensity-score matching, presented in the supplementary appendix), the impact of unidentified confounders is an unavoidable limitation of observational studies. However, it has been argued that a well-conducted observational cohort study can provide the same level of internal validity as randomized controlled trials. Moreover, observational studies are carried out on real-world populations, and therefore can reach higher levels of external validity compared to RCTs. Second, the OBSERVANT study did not collect extensive details regarding coronary revascularization strategies, including number and type of stent and grafts and PCI/CABG target vessels, or information on completeness of revascularization. Third, data on noninvasive functional assessments of ischemia using nuclear perfusion imaging, echocardiography, or magnetic resonance imaging were not collected in the database. Finally, another limitation of the present study is that the outcome events were not defined according to Valve Academic Research Consortium (VARC) [29] . The reason is that such definitions are specifically designed to define complications after TAVR and therefore may be misleading to illustrate complications after SAVR, likely resulting in their overestimation. Furthermore, the OBSERVANT study was started on before these guidelines were published.
CONCLUSIONS
In patients with associated severe AS and CAD a fully percutaneous treatment (TAVR and staged or concomitant PCI) was comparable to surgical treatment (SAVR and concomitant CABG) with respect to the early and mid-term risk of death from any cause, myocardial infarction, stroke and unplanned revascularization. Further studies with newer generation TAVI devices and longer term Academic Research Consortium-2 consensus document. J Thorac Cardiovasc Surg. 2013; 145:6-23 
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